Tolvaptan Drug Asset Due Diligence Report 2026

This Tolvaptan Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

241

Registered trials

108

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Tolvaptan can convert its Small molecule drug profile and AVPR2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Tolvaptan (query alias: tolvaptan)
Modality / target	Small molecule drug; AVPR2; AVPR2 antagonists
Highest global status	Approved
Originator	Otsuka Holdings Co., Ltd.
Active developers	Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Holdings Co., Ltd.

The MCP disease footprint includes Ascites, Polycystic Kidney, Autosomal Dominant, Edema, Cardiac. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
ChiCTR2600118902	Phase 4	Pending	222	Incidence of hyponatremia on postoperative day 7
ChiCTR2500109727	Phase 4	Completed	80	Expected volume growth rate
CTR20254014	Not Applicable	已完成	64	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

#569 Safety and efficacy of Tolvaptan in real-world high-risk patients with ADPKD—a single center experience

Not Applicable; n=45; evaluation: Positive. Reported fields: Adverse Event: mild elevation of liver enzymes = 13.3%; all ≤2 ULN

Safety and efficacy of tolvaptan in real‑world Japanese patients with autosomal dominant polycystic kidney disease: final results of SLOW‑PKD surveillance

Not Applicable; n=1676; evaluation: Positive. Reported fields: Adverse Event: hepatic function abnormal = 9.6%

Interventions for preventing the progression of autosomal dominant polycystic kidney disease

Not Applicable; n=8016; evaluation: Negative. Reported fields: -; TKV growth = -2.7 mL/cm ( -3.24 to -2.16)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Tolvaptan addresses Ascites, Polycystic Kidney, Autosomal Dominant, Edema, Cardiac. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2023-01-01	Swixx and Otsuka expand partnership with Lupkynis® and Abilify®	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “A tablet of tolvaptan and at least one binder processed with spray granulation”. The milestone feed surfaced a patent-application signal described as “A tablet of tolvaptan and at least one binder processed with spray granulation”. The milestone feed surfaced a patent-application signal described as “Stable pharmaceutical compositions comprising amorphous tolvaptan”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO